PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine.
Arribas AJ, Gaudio E, Napoli S, Yvon Herbaux CJ, Tarantelli C, Bordone RP, Cascione L, Munz N, Aresu L, Sgrignani J, Rinaldi A, Kwee I, Rossi D, Cavalli A, Zucca E, Stussi G, Stathis A, Sloss C, Davids MS, Bertoni F.
Arribas AJ, et al. Among authors: sgrignani j.
bioRxiv [Preprint]. 2023 Nov 16:2023.11.14.566994. doi: 10.1101/2023.11.14.566994.
bioRxiv. 2023.
PMID: 38014209
Free PMC article.
Preprint.